Zetomipzomib is a small molecule commercialized by Kezar Life Sciences, with a leading Phase II program in Polymyositis. According to Globaldata, it is involved in 7 clinical trials, of which 4 were completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Zetomipzomib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Zetomipzomib is expected to reach an annual total of $19 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Zetomipzomib Overview

Zetomipzomib maleate is under development for the treatment of systemic lupus erythematosus with or without lupus nephritis, autoimmune hepatitis and idiopathic inflammatory myopathy including dermatomyositis and polymyositis. It is administered by subcutaneous and intravenous route of administration. The drug candidate is an analog of ONX 0914 and acts by targeting immunoproteasome LMP7. It was also under development for acquired (autoimmune) hemolytic anemia, immune thrombocytopenic purpura.

Kezar Life Sciences Overview

Kezar Life Sciences is a clinical-stage biotechnology company. It discovers and develops small molecule therapies to treat autoimmunity and cancer. The company offers products such as KZR-616 and KZR-261. It is involved in the treatment of various autoimmune diseases, lupus nephritis, solid tumors, oncology, immunology and idiopathic inflammatory myopathies. Kezar Life Sciences’ product KZR-616 is a selective immunoproteasome inhibitor used for the treatment of chronic immune-mediated diseases. The company also discovers and develops targeted cancer and immuno-oncology indications using its protein secretion pathway research platform. Kezar Life Sciences is headquartered in South San Francisco, California, the US.

The operating loss of the company was US$54.7 million in FY2021, compared to an operating loss of US$43 million in FY2020. The net loss of the company was US$54.6 million in FY2021, compared to a net loss of US$41.7 million in FY2020.

For a complete picture of Zetomipzomib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.